30 results about "C-type natriuretic peptide" patented technology

The present invention provides variants of C-type natriuretic peptide (CNP) comprising one or more deletions; additions of and / or substitutions with natural amino acids, unnatural amino acids and / or peptidomimetics (including peptide bond isosteres); amino acid extensions; and / or other chemical moieties such as, e.g., poly(ethylene glycol) and hydrophobic acids. The CNP variants are useful as therapeutic agents for the treatment of diseases responsive to CNP, including but not limited to bone-related disorders such as, e.g., skeletal dysplasias and achondroplasia, and vascular smooth muscle disorders such as, e.g., restenosis and arteriosclerosis.

The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and / or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.

An isolated chimeric peptide consisting of one or two added peptides and an object peptide wherein the added peptide is bonded to the N-terminus, the C-terminus or both of the object peptide, wherein if the added peptides are bound to both terminals, the two added peptides may be the same or different; and physiological activity of the object peptide is still retained, wherein the object peptide is a natural physiologically active peptide selected from the group consisting of an atrial natriuretic peptide, a brain natriuretic peptide, a C-type natriuretic peptide, motilin, a glucagon-like peptide 1, parathyroid hormone, and calcitonin, or a derivative of any thereof, wherein the derivative has one or more amino acid(s) deleted from the amino acid sequence of a natural physiologically active peptide and has the desired physiological activity.

A means of measuring and monitoring skeletal growth rate using a plasma analyte, amino-terminal C-type natriuretic peptide (NT-CNP). Plasma NT-CNP concentrations reflect the potential for further growth of the immature skeleton. Measurement of plasma NT-CNP in a subject, when related to the mean of an appropriate age and gender matched set of control subjects, provides an index of the severity of a growth disorder not otherwise available and facilitates diagnosis in children with undetected osteo-chondrodysplasias or other intrinsic disorders of the growth plate. The invention also provides a means of detecting and monitoring potentially harmful effects of drugs and other factors on skeletal growth long before they are evident using current methods in clinical practice.

It is an object of the present invention to provide a new agent for the treatment of alopecia, the agent being not only effective and safe for, in particular, alopecia areata, androgenetic alopecia in a male, androgenetic alopecia in a female, female pattern alopecia, postpartum alopecia, seborrheic alopecia, alopecia pityroides, senile alopecia, cancer chemotherapy drug-induced alopecia, and alopecia due to radiation exposure, but also effective for a target having resistance to treatment with minoxidil or finasteride, there being no side effects such as an itching sensation, irritation, or feminization, and no contraindications, the agent suppressing dandruff or having a therapeutic effect for white hair, and the therapeutic effect for alopecia being maintained for a long period even when use of the agent is stopped.The solution means of the present invention is an agent for the treatment of alopecia containing as an active ingredient a C-type natriuretic peptide (CNP), a B-type natriuretic peptide (BNP), a derivative of these NPs, a chimeric peptide of these NPs, or a derivative of a chimeric peptide of these NPs.

The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and / or CNP-associated symptom or component.

The problem to be solved by the present invention is to provide an effective and safe therapeutic preparation for rhinitis, which not only has significant effects on improvement in rhinitis, in particular allergic rhinitis, but also is rapid in manifestation of efficacy, fast-acting, and long-lasting, without local side effects.Means for solving the problem is a therapeutic preparation for rhinitis, in particular allergic rhinitis, comprising C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

The invention provides NP compounds such as proteins, peptides, peptidomimetics, derivatives and analogs for treating retinal disorders and diseases.

The invention provides a method and system for developing and using diagnoses of cancer and sepsis in canine subjects using Thymidine kinase (TK), c-reactive protein (CRP), and C-type natriuretic peptide (CNP) as biomarkers. The level of each biomarker may be measured and an index may be computed using a two- or a three-biomarker method. The invention provides a predefined scale for the index where each range of the index matches a health condition. The latter allows a practitioner, through computing an index value of a patient, to determine the health status of the patient by comparing the index value to the predefined scale.

The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

Methods are provided for in vitro maturation (IVM) of bovine oocytes that include steps of (a) pre-culturing bovine germinal vesicle (GV) oocytes in the presence of C-type natriuretic peptide (CNP) and (b) subsequently culturing the oocytes of (a) for an extended duration in medium containing follicle stimulating hormone (FSH), luteinizing hormone (LH), 17β-estradiol (E2), epidermal growth factor (EGF), and fetal bovine serum (FBS).

The present invention provides application of C-type natriuretic peptide in the preparation of a topical contraceptive and a sperm function test reagent. It is found in studies that at the time of ovulation, C-type natriuretic peptide is expressed at the ampulla of oviduct, at a site of fertilization, and this can induce the chemotactic movement of sperms toward an ovum to accomplish the fertilization. If a certain amount of C-type natriuretic peptide is added into the genital tract of a female mammal, or the C-type natriuretic peptide is incubated with the sperms, such that the concentration gradient distribution of the C-type natriuretic peptide in the oviduct is changed, the sperms cannot chemotactically move toward the ovum along the concentration gradient, and thus the fertilization is blocked.

The problem to be solved by the present invention is to provide a safe and efficacious therapeutic agent for dermatitis which is not only safe and efficacious for patients with dermatitis, in particular atopic dermatitis, but also significantly effective for severe cases that are judged to be intractable by conventional external preparations, and which is also safely applicable to affected areas such as the face and neck, as well as to subjects with sensitive skin, such as infants and females. Furthermore, the invention aims to provide an external preparation that is efficacious as skin care cosmetics having effects to improve elasticity and wrinkles of the skin, moisturizing effects, and hair-growth effects. The means for solving the problem is a skin external-preparation composition, in particular, a therapeutic agent for dermatitis or a skin texture-improving agent, having C-type natriuretic peptide (CNP) or B-type natriuretic peptide (BNP) as the active ingredient.

The invention discloses a novel natriuretic peptide chimera CNAAc which has the functions of vasodilation, diuresis and myocardial protection. The CNAAc is a novel natriuretic peptide molecule formed by adding an annular structure of ANP (Atriopeptin) and c-terminus on an amino terminal of CNP (C-type Natriuretic Peptide) (as shown in the drawing). The natriuretic peptide chimera has the functions of endothelium-independent vasodilation and strong diuresis. The vasodilation function of the natriuretic peptide chimera CNAAc is greatly superior to that of the natural natriuretic peptide ANP or CNP, and the natriuretic peptide chimera CNAAc possibly exerts the effec through an NPR / cGMP / PKG signal channel. The CNAAc can be used for obviously inhibiting the cardiac hypertrophy of a rat during the generation of the cardiac failure and improving the myocardial enzymology indexes and the cardiac functions of the rat so as to obviously relieve the myocardial infarction degree and the myocardial fibrosis degree of the rat with the cardiac failure. The novel natriuretic peptide chimera with the functions of the myocardial protection and the cardiac failure resistance can be applied to academic research and can be possibly prepared into novel medicines for preventing and treating cardiac failure in clinical application. Thus, the novel natriuretic peptide chimera has good scientific research values and clinical application prospects.